Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 4/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.43 |
| ▸ | PI4KA | P42356 | 5/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 5/20 | 0.34 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28474962 | 0.79 | LIMK1 (0.39) | LIMK1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL13077902 | 0.77 | ADORA2A (0.51) | LIMK1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL19376297 | 0.77 | LIMK1 (0.41) | LIMK1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL459311 | 0.77 | LIMK1 (0.41) | LIMK1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL12621162 | 0.74 | LIMK1 (0.39) | LIMK1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL23917272 | 0.71 | LIMK1 (0.47) | LIMK1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL463027 | 0.69 | ADK (0.48) | LIMK1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL13593762 | 0.69 | LIMK1 (0.44) | LIMK1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL8336964 | 0.68 | NOS2 (0.44) | LIMK1ADORA2AADORA1ADORA2B | |
| SCHEMBL26976 | 0.64 | ADORA2A (0.61) | LIMK1ADORA2AADORA1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4242212-A2 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | Takeda Pharmaceutical Company Limited (JP) | 2023-09-13 | — | — | EP | disclosed |
| WO-2019180683-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-26 | — | — | WO | disclosed |
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2018-07-12 | — | — | US | disclosed |
| EP-3311818-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | Pharmacyclics, LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2017-12-21 | — | — | US | disclosed |
| US-9795605-B2 | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors | PHARMACYCLICS LLC (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2307025-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | PHARMACYCLICS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-9556182-B2 | Inhibitors of Bruton's tyrosine kinase | Pharmacylics LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9278100-B2 | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors | PHARMACYCLICS LLC (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2560007-A1 | Identification of bruton's tyrosine kinase inhibitors | Pharmacyclics, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-2548558-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC AS INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics, Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2543375-A1 | Pyrrolo-pyrimidine analogues as inhibitors of bruton's tyrosine kinase | Pharmacyclics, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120296089-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120277225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120202264-A1 | INHIBITORS OF IL2-INDUCIBLE T-CELL KINASE | PHARMACYCLICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2010009342-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2008121742-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LIMK1 919/4885ADORA2A 4471/4885ADORA1 4765/4885 |
| US-20120296089-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LIMK1 919/4885ADORA2A 4471/4885ADORA1 4765/4885 |
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | LIMK1 618/4885ADORA2A 4718/4885ADORA1 4858/4885 |
| US-20120277225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LIMK1 919/4885ADORA2A 4471/4885ADORA1 4765/4885 |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LIMK1 919/4885ADORA2A 4471/4885ADORA1 4765/4885 |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | LIMK1 618/4885ADORA2A 4718/4885ADORA1 4858/4885 |
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | BTK, ABL1, LYN | LIMK1 618/4885ADORA2A 4718/4885ADORA1 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.